US Pharmaceutical Drug Delivery Market

The US pharmaceutical drug delivery market is experiencing growth due to the increased demand for advanced lines of treatment, namely, biologics, biosimilars, and personalized medicines. These therapies need a very elaborate and complex delivery mechanism to ensure that administration is done in a targeted, efficient, and safe manner. In addition, the rising number of chronic diseases, such as diabetes, cancer, and heart problems, is driving the search for new delivery systems like injectables, sustained-release formulations, and transdermal patches. The latest developments in drug delivery devices, along with the increasing adoption of self-administration tools, are contributing to the growth of the market. Additionally, the R&D spending of major pharmaceutical companies is a significant driver of this market. The combination of patient preference for easy and non-invasive delivery methods, the focus on the enhancement of treatment results, and the above-mentioned factors provides the US market with a significant boost.

Some of the prominent players operating in the market include Johnson & Johnson Services, Inc. (US), Pfizer Inc. (US), F. Hoffmann-La Roche (Switzerland), Becton, Dickinson and Company (US), Merck & Co., Inc. (US), Amgen, Inc. (US), AbbVie Inc. (US), Gilead Sciences, Inc. (US), Eli Lilly and Company (US), Bristol-Myers Squibb (US), Biogen (US), Baxter International (US), West Pharmaceutical Services (US), Catalent Pharma Solutions (US), and Novartis (Switzerland).

To know about the assumptions considered for the study download the pdf brochure

In December 2024, Becton, Dickinson and Company (BD) (US) expanded its injectable drug delivery portfolio by launching the BD EffiFlow Advanced Prefillable Syringe Platform. This new platform is designed to enhance compatibility with biologics, reduce extrusion force, and improve safety during the administration of high-viscosity drugs. This expansion reinforces BD’s leadership in prefillable syringes and addresses the growing demand for self-injection solutions in the biologics and specialty drug markets across the US.

In November 2024, West Pharmaceutical Services (US) launched its next-generation NovaPure 3.0 Components. These components feature improved elastomer purity, enhanced container-closure integrity, and optimized performance for sensitive biologics and mRNA formulations. This product launch underscores West’s commitment to high-performance containment and delivery systems, supporting its growth in advanced sterile drug packaging within the US pharmaceutical sector.

Johnson & Johnson Services, Inc. (US)

Johnson & Johnson's pharmaceutical division, Janssen, which is the largest and most influential in the US pharmaceutical drug delivery market, has made a significant impact globally. The company has extensive R&D capabilities and continues to invest in new delivery systems, which is why it has been able to maintain such a strong position. J&J's strong expertise in materials science, device engineering, and formulation technology facilitates the development of very stable and patient-friendly delivery mechanisms. These support the demand for biologics, oncology treatments, and immunotherapies. The company is capable of producing depot injections, transdermal systems, and smart, connected devices, all of which can enhance patient adherence and therapeutic outcomes. Besides having a large manufacturing capacity, Johnson & Johnson is also a strategic partner in drug-device combination products and continuously focuses on innovation in this area.

Pfizer Inc. (US)

Pfizer Inc. holds a prominent position in the US pharmaceutical drug delivery market. The company benefits from advanced therapeutics, mRNA technology, and drug-device combinations. Pfizer’s innovative work in the delivery of nucleic acid-based technology, such as lipid nanoparticle (LNP) systems, which are used in mRNA vaccines and new gene therapy candidates, has made it a leader in next-generation drug delivery technology. Moreover, Pfizer manufactures a wide range of medicines for oral, injectable, inhalation, and sustained-release purposes, which are readily available, ensuring therapeutic precision and patient adherence through treatments for immunology, oncology, cardiovascular, and infectious diseases. The company’s strong collaboration partners, extensive formulation expertise, and large US manufacturing capacity all facilitate rapid scaling and dependable supply of advanced delivery systems. Alongside this, digital health integration, self-administration technology, and improved delivery methods for complex biologics are other factors that are continuously developing and keeping Pfizer’s status as one of the dominating and progressive companies in the US pharmaceutical drug delivery market.

Becton, Dickinson and Company (US)

Becton, Dickinson and Company (BD) is one of the major companies dominating the US pharmaceutical drug delivery market. Its strengths mainly lie in the areas of injectable delivery systems, prefillable syringes, specially designed safety devices, and drug-device combination platforms. BD, being a global leader in injection technologies, supplies a large portion of the syringes, needles, and containment systems that pharmaceutical companies use for biologics, vaccines, and high-viscosity formulations, which are efficient and advanced. Among the company’s many innovations are next-generation polymer syringes, ultra-low-residual-volume systems, and ergonomic devices for self-injection, all of which promote the growing trend of home care and self-administration in the US market. BD's capability of large-scale manufacturing, knowledge of regulations, and its longstanding ties with large pharmaceutical companies make it easy for its delivery systems to be part of commercial drug programs. Additionally, the continuous investment in automation, digital monitoring, and contamination-control technologies provides a further layer of performance, safety, and reliability to BD’s drug delivery solutions, thereby firmly establishing the company as a trusted leader through which the US pharmaceutical drug delivery market advances.

Market Ranking

The major players in the US pharmaceutical drug delivery market are Johnson & Johnson, Pfizer, Merck, AbbVie, and BD. These companies have invested significantly in advanced drug-device combination technologies. They are increasingly focusing on biologics and specialty medicines that rely on sophisticated delivery systems. This focus is supported by strong research & development pipelines aimed at developing precision therapies and ensuring easy access for patients.

The demand for self-administration solutions is increasing, with auto-injectors, prefilled syringes, and wearable injectors being the most popular options. These innovations are driving progress within the companies that produce them. Additionally, the growing need for targeted delivery systems in the treatment of cancer, immune disorders, and chronic diseases is contributing to the adoption of this technology. Manufacturers of these solutions benefit from large-scale production capabilities and often engage in strategic partnerships with biotech companies. As a result, their delivery methods comply with existing regulations, enhancing their competitive strength in the market.

The growing use of long-acting injectables, controlled-release formulations, and next-generation delivery platforms, such as lipid nanoparticles and smart connected devices, is simultaneously driving sales for these leading players in the US market.

Related Reports:

US Pharmaceutical Drug Delivery Market by Route of Administration [Oral (Tablet, Capsule), Injectable, Topical (Cream, Transdermal, Suppositories), Ocular, Nasal, Transmucosal, Implantable], Application (Cancer, Diabetes), Care Setting - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com